Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
Pathology - Research and Practice · 2023
DOI: 10.1016/j.prp.2023.154470 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Tannaz Dehghani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Lorestan University of Medical Sciences, Lorestan, Iran. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 287 Literaturangaben.
Abstract (Originalsprache)
The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use protective mechanisms to facilitate immune evasion, which leads to potentiated cancer survival and proliferation. In this light, many blocking anti-bodies have been developed to negatively regulate checkpoint molecules, in particular, programmed cell death protein 1 (PD-1) / PD-ligand 1 (L1), and bypass these immune suppressive mechanisms. Meanwhile, anti-PD-1 anti-bodies such as nivolumab, pembrolizumab, cemiplimab, and sintilimab have shown excellent competence in successfully inspiring immune responses versus NSCLC. Accordingly, the United States Food and Drug Administration (FDA) has recently approved nivolumab (alone or in combination with ipilimumab) and pembrolizumab (alone or in combination with chemotherapy) as first-line treatment for advanced NSCLC patients. However, PD-1 blockade monotherapy remains inefficient in more than 60% of NSCLC patients, and many patients don't respond or acquire resistance to this modality. Also, toxicities related to anti-PD-1 anti-body have been progressively identified in clinical trials and oncology practice. Herein, we will outline the clinical benefits of PD-1 blockade therapy alone or in combination with other treatments (e.g., chemotherapy, radiotherapy, anti-angiogenic therapy) in NSCLC patients. Moreover, we will take a glimpse into the recently identified predictive biomarkers to determine patients most likely to suffer serious adverse events to decrease untoward toxicity risk and diminish treatment costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Lorestan University of Medical Sciences, Lorestan, Iran.
- National Institute for Genetic Engineering and Biotechnology (NIGEB), P.O. Box: 14965/161, Tehran, Iran.
- Department of Surgery, Alborz University of Medical Sciences, Karaj, Alborz, Iran.
- Departmant of Genetic, Babol University of Medical Science, Babol, Iran.
- Colife Pathobiology Laboratory, Tehran, Iran.
- Prosthetic Dental Techniques Department, Al-Mustaqbal university College, Babylon 51001, Iraq.
Zitieren
APA
Dehghani, T., Shahrjerdi, A., Kahrizi, M. S., Soleimani, E., Ravandeh, S., Merza, M. S., Rahnama, N., Ebrahimzadeh, F., & Bakhshesh, M. (2023). Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154470
Vancouver
Dehghani T, Shahrjerdi A, Kahrizi MS, Soleimani E, Ravandeh S, Merza MS, et al. Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154470
BibTeX
@article{Dehghani2023,
author = {Dehghani, Tannaz and Shahrjerdi, Alireza and Kahrizi, Mohammad Saeed and Soleimani, Elnaz and Ravandeh, Saeideh and Merza, Muna S and Rahnama, Negin and Ebrahimzadeh, Farnoosh and Bakhshesh, Morteza},
title = {Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances},
journal = {Pathology - Research and Practice},
year = {2023},
doi = {10.1016/j.prp.2023.154470}
}
EUVIMED